The cross-licensing of the other party`s patent portfolios allows both companies to focus on helping people with diabetes innovate in future products and services, while avoiding the distraction of potential legal differences. You can cancel your account at any time by using the “Delete Account” feature or by contacting us here: www.tandem.net/contact-us. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, addressing risks and uncertainties that could cause actual results to differ materially from the expected or projected results in the forward-looking statements. These forward-looking statements relate, among other things, to the distribution agreement between the company and Rubin Medical and the expected availability of the company`s products outside the United States. The company`s actual results may differ materially from those indicated in these forward-looking statements, due to numerous risks and uncertainties, including risks associated with the development of new products in general, including potential delays in the company`s product development programs; possible actions to be taken by regulators or government authorities, including the company`s potential not to achieve the “CE” mark for the company`s products if expected; The potential to terminate the company`s agreement with Rubin Medical; as well as other risks identified in Tandem`s latest Annual Report on Form 10-K or quarterly reports on Form 10-Q and other documents we submit to the Securities and Exchange Commission.